Global Radiofrequency Ablation Market Research Report
- Report Code: HE 1129
- Publish Date: Upcoming
The Global Radiofrequency Ablation Market, mainly driven by increasing aging population with high risk of chronic diseases and increasing procedures through minimal invasive surgery was valued at $1918 million in 2013 and is expected to reach $3854 million by 2018.
Temperature Controlled Devices, Fluid Cooled Devices, and Robotic Navigation-Catheter Manipulation Systems are the technologies that are part of Radiofrequency Ablation Therapy.
Radiofrequency ablation is used for cancers of liver, lung, colon and benign tumor removal. It has shown a high success rate against liver cancer or hepatocellular carcinoma, which according to 2011 estimates has affected over 500,000 people over the world. It is also used when patients have been unresponsive to chemotherapy or other medical conditions which render other surgical procedures as non-viable.
Radiofrequency ablation can be applied widely across most types of cancers and benign tumors. High incidence of hepatocellular carcinoma in Asia and Africa is expected to drive the market for RFA in these regions. Several other factors are also driving this market such as the minimally invasive nature of the procedure as it is favored by patients and physicians alike.
Emerging markets such as India, China, and Brazil have undergone significant economic development over the past decade. This development has also led to an increase in healthcare availability in these countries. Also, as these countries have relatively modest GDP per capita levels and highly variable healthcare systems, the need for inexpensive radiofrequency ablation devices is emerging as an important factor. It has provided an opportunity for ablation devices companies, to have an established and growing market in these countries.
European market is challenging, as it is a heterogeneous region in terms of regulatory and reimbursement approaches, with every country having its own unique characteristics. Aging Japanese population, which is at a high risk of developing chronic diseases such as cancer and cardiac disorders, will ultimately lead to growth in procedure volume in the future.
This report also provides an extensive competitive landscaping of companies operating in radiofrequency ablation market. The key players in radiofrequency ablation market are Covidien (Ireland), Boston Scientific (U.S.), Biosense Inc. (U.S.), St. Jude Medical (U.S.), AngioDynamics (U.S.) and Medtronic Inc. (U.S.).
Segment and country specific Company shares, News & Deals, M&A, segment specific pipeline products, product approvals and product recalls of the major companies have been detailed.
Customization Options:
The market data enables you to customize the MMM assessments that meet your company’s specific needs. Customize to get comprehensive industry standard and deep dive analysis of the following parameters:
Product Analysis
- Usage pattern (in-depth trend analysis) of products (Segment wise)
- Product Matrix which gives a detailed comparison of product portfolio of each company mapped at country and sub segment level
- End-user Adoption rate analysis of the products (Segment wise and Country wise)
- Comprehensive coverage of Product approvals, Pipeline products and Product recalls
Epidemiology Data
- Country specific Prevalence of cancer and cardiovascular disorders
- Country specific Patient pool of cancer and cardiovascular disorders.
- Disease progression (Pattern analysis)
Surgeons/Physicians Perception Analysis
- Fast turn-around analysis of Surgeons response to market events and trends
- Surgeons opinion about products from different companies
- Surgeons qualitative inputs on epidemiology date
Brand/Product Perception Matrix
- Comprehensive study of customers perception and behavior through our inbuilt social connect tool checking the virality and tonality of blogs
- Analysis of overall brand usage and familiarity and brand advocacy distribution (Detractor/Neutral/Familiar)
1 Introduction
1.1 Objective of the study
1.2 Market Definitions
1.3 Market Segmentation & Aspects Covered
1.4 Research Methodology
1.4.1 Assumptions (Market Size, Forecast, etc)
2 Executive Summary
3 Market Overview
Please fill in the form below to receive a free copy of the Summary of this Report
Please visit http://www.micromarketmonitor.com/custom-research-services.html to specify your custom Research Requirement
| PRODUCT TITLE | PUBLISHED | |
|---|---|---|
|
|
Americas Radiofrequency Ablation The Global Radiofrequency Ablation Market, was pegged at $1160 million in 2013 and expected to be $2313 million by 2018. The key players in Radiofrequency Ablation sector are Covidien (Ireland), Boston Scientific (U.S.), Biosense Inc. (U.S.), St. Jude Medical (U.S.), AngioDynamics (U.S.) and Medtronic Inc. (U.S.). |
Upcoming |
|
|
Asia-Pacific Radiofrequency Ablation The Asia-Pacific Radiofrequency Ablation Market was pegged at $303 million in 2013 and expected to be $650 million by 2018. The key players in Asia-Pacific Radiofrequency ablation sector are Covidien (Ireland), Boston Scientific (U.S.), Biosense Inc. (U.S.), St. Jude Medical (U.S.), AngioDynamics (U.S.) and Medtronic Inc. (U.S.). |
Upcoming |
|
|
European Radiofrequency Ablation The European Radiofrequency Ablation Market was pegged at $1160 million in 2013 and expected to be $2313 million by 2018. The key players in European radiofrequency ablation therapy sector are Covidien (Ireland), Boston Scientific (U.S.), Biosense Inc. (U.S.), St. Jude Medical (U.S.), AngioDynamics (U.S.) and Medtronic Inc. (U.S.). |
Upcoming |
